Korsana Biosciences (KRSA) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 90.0% versus a loss of 5.8%. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.44 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | MAZE |
|---|---|---|
| Share price | $33.51 | $25.88 |
| Market cap | $1.53B | $1.44B |
| 1-day change | +6.37% | -1.41% |
| YTD return | +276.94% | -36.64% |
| 1-year return | +89.97% | -5.78% |
| 5-year return | -91.10% | — |
| EPS (TTM) | $-7.07 | $-2.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.36 | $53.65 |
| 52-week low | $7.19 | $21.95 |
| Distance from 52-week high | -43.55% | -51.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +31.30% | +137.64% |
| Average volume | 29.26K | 560.26K |
| Shares outstanding | 45.54M | 55.55M |
| Employees | 19 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed MAZE by 95.7 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
KRSA vs MAZE FAQ
Which is bigger, Korsana Biosciences or Maze Therapeutics?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.44B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, KRSA or MAZE?
KRSA returned +89.97% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Maze Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Korsana Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics.